Release Date: February 10, 2026
Expiration Date: February 10, 2027
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in early-stage, resectable, non–small cell lung cancer (NSCLC). In this educational program, these experts lead case-based panel discussions on the latest clinical advances in managing resectable NSCLC with immunotherapy and targeted treatments. The expert panel also shares their perspectives on the latest data and clinical pearls from their practices in managing early-stage, resectable NSCLC.
This educational activity is an archive of the live symposium held on January 29, 2026.
Target Audience
This educational activity is directed toward thoracic oncologists, medical oncologists, pathologists, nurse practitioners, physician assistants, nurses, and other health care providers involved in managing resectable, early-stage NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess key findings from pivotal clinical trials evaluating neoadjuvant, adjuvant, and perioperative immunotherapy for resectable, early-stage, non–small cell lung cancer (NSCLC)
- Evaluate the latest evidence for the use of targeted therapies for EGFR-mutant, resectable, early-stage NSCLC in the neoadjuvant and adjuvant settings
- Apply best practices for biomarker testing to guide personalized selection of perioperative systemic therapy in patients with NSCLC
- Implement multidisciplinary strategies to mitigate treatment-related toxicities associated with perioperative immunotherapies and EGFR-targeted tyrosine kinase inhibitors
Mara Antonoff, MD, FACS
Associate Professor
Program Director of Education
Department of Thoracic and Cardiovascular Surgery, Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Merck, Regeneron
Laura Alder, MD
Assistant Professor of Medicine
Thoracic Oncology Program
Duke Cancer Center
Duke University Medical Center
Durham, NC
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Boehringer Ingelheim, Foundation Medicine, Genentech, Lilly, Nuvation Bio, OncoHost, Regeneron; Grant/Research Funding: BerGenBio, Iambic Therapeutics, Lung Cancer Initiative, NTT Data, ORIC Pharmaceuticals, Phanes Therapeutics
Stephanie Worrell, MD, FACS
Clinical Associate Professor, Surgery
Section Chief, Thoracic Surgery
Associate Program Director, General Surgery Residency
The University of Arizona College of Medicine—Tucson
Sierra Vista, AZ
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Intuitive Surgical; Grant/Research Funding: American Association for Thoracic Surgery
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
